Bevacizumab maintenance in metastatic colorectal cancer: How long?

doi:10.12998/wjcc.v2.i11.717

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 11

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5714)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series.

Item

Count

PDF

384

WORD

252

HTML

2431

Figures (1-7)

234

Sum=3301

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1032

Download

1381

Sum=2413

Nov 16, 2014 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Nov 16, 2014; 2(11): 717-723
Published online Nov 16, 2014. doi: 10.12998/wjcc.v2.i11.717

Full Size Figure Download Figure

Figure 4 Thorax computed tomography-scan after 4 mo of maintenance treatment. The disease has completely regressed according to RECIST criteria (November 2009).

Citation: Stefano AD, Moretto R, Cella CA, Romano FJ, Raimondo L, Fiore G, Pietro FD, Pepe S, Placido SD, Carlomagno C. Bevacizumab maintenance in metastatic colorectal cancer: How long? World J Clin Cases 2014; 2(11): 717-723
URL: https://www.wjgnet.com/2307-8960/full/v2/i11/717.htm
DOI: https://dx.doi.org/10.12998/wjcc.v2.i11.717